Author: Gorczynski, R.M.

Source: Current Pharmaceutical Design, Volume 7, Number 11, 1 July 2001 , pp. 1039-1057(19)

Publisher: Bentham Science Publishers

Abstract:

This review examines the evidence, both from experimental models and Numerous clinical settings, that has suggested that suppression of acute allograft Rejection correlates with a relative decrease in type-1 cytokine production and an increase in type-2 cytokine production. This correlation has spurred studies on cytokine gene polymorphisms, to assess evidence that certain cytokine-producing genotypes are associated with increased incidence of transplant rejection, and also an interest in the value of monitoring cytokine profiles post-transplantation in long-term follow-up of transplant patients. An appraisal is given of the potential for cytokine gene therapy in transplantation, using both dendritic cells (DC) and graft tissue itself as target cells. Along the same lines, gene-targeting of DCs to increase or decrease expression of molecules (CD40/CD80/CD86/CD200) believed to control the polarization of T cell development (and cytokine production) is discussed. The review concludes with consideration of the possibility that one future goal of the pharmaceutical industry will be to develop novel immunosuppressants with selective inhibitory action on the production of distinct cytokines.

Keywords: Cytokine Therapeutics; Cytokines; Allograft Rejection; dendritic cells (DC); Hepatic APCs; Skin Graft Rejection Models; Corneal Grafts Models; Bone Marrow Transplantation Models; TRANSCRIPTIONAL REGULATION

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397618

Publication date: 2001-07-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Gorczynski, R.M.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers